NCT02573831

Brief Summary

Oxycodone is used to treat pain in early labor, however the effect of oxycodone to placental or fetal circulation has not been evaluated. Oxycodone is increasingly used to treat labor pain in the early phase. The aim of the randomised, double blinded, placebo controlled study was to evaluate the effects of oxycodone in placental circulation, efficacy and safety of oxycodone and the effects to the newborn.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
22

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Feb 2015

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2015

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

October 8, 2015

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 12, 2015

Completed
8.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

March 16, 2023

Status Verified

March 1, 2023

Enrollment Period

8.9 years

First QC Date

October 8, 2015

Last Update Submit

March 14, 2023

Conditions

Keywords

laborpainoxycodoneplacenta

Outcome Measures

Primary Outcomes (1)

  • placental blood flow

    Placental blood flow is measured with doppler ultrasound

    from zero hours to two hours after the first study drug

Secondary Outcomes (1)

  • uterine arterial flow

    from zero hours to two hours after the first study drug

Study Arms (2)

Placebo

PLACEBO COMPARATOR

The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if needed

Drug: Placebo

Oxycodone

EXPERIMENTAL

The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more

Drug: Oxycodone

Interventions

The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more

Oxycodone

The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more

Placebo

Eligibility Criteria

Age18 Years - 65 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • oxycodone planned for pain relief
  • age 18 years or more
  • Informed consent obtained
  • Full term pregnancy

You may not qualify if:

  • No oxycodone planned
  • age less than 18 years
  • No informed consent
  • not full term pregnancy
  • Other contraindication to oxycodone

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kuopio University Hospital

Kuopio, Northern Savonia, 70029, Finland

Location

Related Publications (1)

  • Alanne L, Kokki H, Mykkanen A, Orden MR, Rinne V, Rasanen J, Kokki M. Oxycodone does not affect placental circulatory physiology during the early first stage of labor-A randomized trial. Acta Obstet Gynecol Scand. 2023 Aug;102(8):1063-1072. doi: 10.1111/aogs.14603. Epub 2023 Jun 21.

MeSH Terms

Conditions

Labor PainPain

Interventions

Oxycodone

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

CodeineMorphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic Compounds

Study Officials

  • Merja Kokki, MD, PhD

    Kuopio University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD

Study Record Dates

First Submitted

October 8, 2015

First Posted

October 12, 2015

Study Start

February 1, 2015

Primary Completion

December 31, 2023

Study Completion

December 31, 2023

Last Updated

March 16, 2023

Record last verified: 2023-03

Data Sharing

IPD Sharing
Will not share

Locations